Skip to content
Q1 '26Q4 '25Q3 '25Q2 '25Q1 '25
$106.51M+159%$47.71M-47.3%$122.06M+33.3%$85.24M-9.7%$41.14M-45.1%
$21.94M-20.0%$21.86M-13.9%$22.47M-24.7%$23.37M-23.1%$27.43M+6.3%
$12.03M-50.4%$19.29M-42.6%$21.91M-39.3%$16.8M-54.6%$24.26M-35.5%
$33.93M-51.7%$40.9M-30.7%$46.58M-29.4%$39.92M-42.5%$70.25M+10.0%
$72.57M+349%$6.81M-78.4%$75.48M+194%$45.32M+81.5%-$29.11M-364%
68.1%+139pp14.3%-20.5pp61.8%+33.9pp53.2%+26.7pp-70.7%-85.5pp
$9.14M+13.3%$7.89M-11.5%$8.43M-10.5%$8.36M+11.9%$8.07M+11.6%
-$7.4M-3.3%-$6.35M+15.3%-$7.46M+9.7%-$7.5M-22.9%-$7.16M-18.2%
$65.17M+280%$455K-98.1%$68.02M+292%$37.82M+100%-$36.27M-832%
$24.4M+2,090%$2.73M-87.4%$27.94M+104%$14.22M-27.9%$1.11M-87.8%
$40.77M+209%-$2.28M-201%$40.08M+999%$23.6M+2,844%-$37.39M-798%
38.3%+129pp-4.8%-7.3pp32.8%+28.9pp27.7%+28.6pp-90.9%-85.3pp
$0.24+204%-$0.01-200%$0.23+1,050%$0.14+1,500%-$0.23-667%
$73.02M+355%$7.27M-77.1%$75.96M+193%$45.79M+81.1%-$28.63M-353%
68.6%+138pp15.2%-19.9pp62.2%+33.9pp53.7%+26.9pp-69.6%-84.7pp
$72.57M+349%$6.81M-78.4%$75.48M+194%$45.32M+81.5%-$29.11M-364%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

What is Ironwood Pharmaceuticals's revenue?
Ironwood Pharmaceuticals (IRWD) generated $361.5M in revenue over the trailing twelve months, up 13.8% year over year.
Is Ironwood Pharmaceuticals profitable?
Ironwood Pharmaceuticals reported $102.2M in net income over the trailing twelve months, a 28.3% net margin.
What are Ironwood Pharmaceuticals's profit margins?
Gross margin is 99.2% and operating margin is 55.4%, with a 28.3% net margin.
What is Ironwood Pharmaceuticals's earnings per share?
Ironwood Pharmaceuticals's diluted EPS over the trailing twelve months is $0.60.
Where does Ironwood Pharmaceuticals's income statement data come from?
Every line is extracted from Ironwood Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.